Full Press Release Details
Therapeutics Appoints Jing Marantz, M.D., Ph.D., M.B.A. to its Board of Directors
SAN DIEGO--(BUSINESS WIRE)--Dec.
13, 2021-- Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a leading
clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities
within liver and respiratory rare diseases, today announced the appointment of Jing Marantz, M.D., Ph.D., M.B.A., an experienced
biopharma industry executive, to its Board of Directors.
"We are very pleased
to welcome Dr. Jing Marantz, to the Arcturus Board," said Joseph Payne, President & CEO of Arcturus. "Jing is
an accomplished industry leader and brings deep clinical and scientific expertise, as well as extensive commercial experience from prominent
biopharma leadership roles where she contributed to the successful development and commercialization of numerous approved medicines. Jing
will be an invaluable addition as Arcturus rapidly advances the development of its novel vaccines and therapeutic candidates."
to join the Arcturus board as the Company advances its vaccine programs, including for COVID-19, while continuing to expand a promising
set of mRNA-based therapeutic candidates in clinical development," said Dr. Marantz. "I look forward to working closely
with the team and contributing to their efforts to bring important new vaccines and medicines to patients."
Dr. Marantz is an experienced
biopharmaceutical industry executive who has held multiple senior level positions in development, medical affairs, business development,
and commercial strategy in several therapeutic areas and rare diseases. She is currently Senior Vice President, Head of Medical Affairs
at Acceleron Pharma, a wholly-owned subsidiary of Merck & Co., Inc. Prior to joining Acceleron in 2020, Dr. Marantz was
Senior Vice President, Head of Medical Affairs at Alnylam Pharmaceuticals where she built the medical affairs organization into a global
footprint across 19 countries and led two successful global product launches (ONPATTRO and GIVLAARI ). Prior to Alnylam, she
served as Vice President, Global Medical Affairs, Head of U.S. Medical Affairs and interim Head of Latin America Medical Affairs
at Alexion Pharmaceuticals where she was responsible for three marketed rare disease products (SOLIRIS , STRENSIQ , and KANUMA ). Dr.
Marantz previously held leadership positions at Biogen, ARIAD, and Millennium Pharmaceuticals across development, medical
affairs, and business development. She currently serves on the Board of Directors for Krystal Biotech, Inc.
About Arcturus Therapeutics
and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a clinical-stage mRNA medicines
and vaccines company with enabling technologies: (i) LUNAR lipid-mediated delivery, (ii) STARR mRNA Technology and (iii) mRNA
drug substance along with drug product manufacturing expertise. Arcturus' diverse pipeline of RNA therapeutic and vaccine candidates
includes mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza, and other programs to potentially treat ornithine transcarbamylase
(OTC) deficiency, and cystic fibrosis along with partnered programs including glycogen storage disease type III (GSD III), hepatitis B
virus (HBV), and non-alcoholic steatohepatitis (NASH). Arcturus' versatile RNA therapeutics platforms can be applied toward multiple
types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing
therapeutics. Arcturus' technologies are covered by its extensive patent portfolio (patents and patent applications issued in the U.S., Europe, Japan, China and
other countries). Arcturus' commitment to the development of novel RNA therapeutics has led to collaborations with Janssen
Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda
Pharmaceutical Company Limited, CureVac AG, Duke-NUS Medical School, and the Cystic Fibrosis Foundation. For more information
visit www.ArcturusRx.com. In addition, please connect with
us on Twitter and LinkedIn.
Trademark Acknowledgements
The Arcturus logo and other
trademarks of Arcturus appearing in this announcement, including LUNAR and STARR , are the property of Arcturus. All other
trademarks, services marks, and trade names in this announcement are the property of their respective owners.
IR and Media Contacts
Arcturus Therapeutics
Deepankar Roy, Ph.D.
Source: Arcturus Therapeutics